Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elzasonan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | BID | P55957 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elzasonan SCHEMBL5159647 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL5159632 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL29379325 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL1649875 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL4604000 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL4604009 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL4604005 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| SCHEMBL5160797 | 0.96 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| SCHEMBL5160805 | 0.96 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| SCHEMBL5606554 | 0.91 | BCL2A1 (0.44) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706147-A2 | COMBINATION THERAPY WITH 5-HT sb 1A /sb AND 5-HT sb 1B /sb RECEPTOR ANTAGONISTS | Recordati Ireland Limited (IE) | 2006-10-04 | — | — | EP | claimed |
| WO-2005070460-A2 | COMBINATION THERAPY WITH 5-HT1A AND 5-HT1B RECEPTOR ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2005-08-04 | — | — | WO | claimed |
| US-20050165025-A1 | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | RECORDATI IRELAND LTD. (IE) | 2005-07-28 | — | — | US | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-1746091-A1 | Process for the preparation of 2-substituted 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one citrate | Pfizer Products Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1706147-A2 | COMBINATION THERAPY WITH 5-HT sb 1A /sb AND 5-HT sb 1B /sb RECEPTOR ANTAGONISTS | Recordati Ireland Limited (IE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1288208-B1 | Process for the preparation of 2-(4-Alkyl-1-Piperazinyl)-Benzaldehyde and -Benzylidenyl compounds by Nucleophilc Aromatic Substitution of 2-Fluorobenzaldehyde with 4-Alkyl-1-Piperazine in Water as Solvent | PFIZER PROD INC (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005070460-A2 | COMBINATION THERAPY WITH 5-HT1A AND 5-HT1B RECEPTOR ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165025-A1 | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | RECORDATI IRELAND LTD. (IE) | 2005-07-28 | — | — | US | disclosed |
| US-6608195-B2 | Dehalogenation, amination between o-fluorobenzaldehyde and a piperazine derivative followed by reaction with a 3-thio-morpholinone; serotonin 1 receptor agonists and antagonists | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030087914-A1 | Process for the preparation of 2-(4-alkyl-1-piperazinyl)-benzaldehyde and -benzylidenyl compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1288208-A1 | Process for the preparation of 2-(4-Alkyl-1-Piperazinyl)-Benzaldehyde and -Benzylidenyl compounds by Nucleophilc Aromatic Substitution of 2-Fluorobenzaldehyde with 4-Alkyl-1-Piperazine in Water as Solvent | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087914-A1 | Process for the preparation of 2-(4-alkyl-1-piperazinyl)-benzaldehyde and -benzylidenyl compounds | TPH1, TPH2, ALDH5A1 | SLC6A2 916/4885SLC6A4 686/4885SLC6A3 1286/4885 |
| US-20050165025-A1 | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | HTR1B, HTR1A, HTR2B | SLC6A2 39/4885SLC6A4 22/4885SLC6A3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.